Статья
КИШЕЧНАЯ МИКРОБИОТА – НОВЫЙ СПУТНИК НА МАРШРУТЕ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ: НЕОЖИДАННЫЕ РОЛИ СТАРЫХ СОСЕДЕЙ
Последнее десятилетие характеризуется значимой переоценкой причастности бактерий кишечника к прогрессированию хронических заболеваний. Пристальное внимание исследователей сконцентрировано на совершенствовании понимания метаболических путей двух компонентов пищи – холина и L-карнитина, которые стоят у истоков формирования триметил-N-оксида (ТМАО). Эта небольшая молекула получила признание в связи с ее способностью влиять на атерогенез, увеличивая, таким образом, риск основных сердечно-сосудистых событий и ухудшая прогноз пациентов. Данная работа нацелена на обcуждение обновленной концепции зависимых от микробиоты кардиометаболических последствий употребления продуктов, богатых четвертичными аминами, а также затрагивает существующие способы влияния на образование ТМАО, их ограничения и направления будущих исследований в этой области.
1. Cambien F, Tiret L. Genetics of cardiovascular diseases: from single mutations to the whole genome. Circulation 2007; 116(15): 1714-24.
2. Zubareva MY, Rozhkova TA, Gorbunova NB, et al. Residual (remaining) risk in patients with very high risk with atherogenic dyslipidemia, are on statin therapy. A prospective study "CRYSTAL". Part 1: The purpose, tasks, design and initial properties included patients. Ateroskleroz i dislipidemii 2013; 1 (10): 26-34. In Russian (Зубарева М.Ю., Рожкова Т. А., Горнякова Н. Б., и др. Резидуальный (остаточный) риск у нездоровых очень высочайшего риска с атерогенными дислипидемиями, находящихся на терапии статинами. Проспективное исследование «КРИСТАЛЛ». Часть 1: Цель, задачки, дизайн и начальные свойства включенных пациентов. Атеросклероз и дислипидемии 2013;1(10):26-34).
3. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21):2195-207.
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTeRHeART study): case-control study. Lancet 2004;364(9438): 937-52.
5. Turnbaugh PJ, Ley RE, Hamady M et al. The human microbiome project. Nature 2007; 449(7164): 804-10.
6. Patel SS, Malakouti M, Cortez MD, et al. Is the gut microbiome the next target for atherosclerosis? JSM Clin Case Rep 2014; 2(5):1055.
7. Vinje S, Stroes E, Nieuwdorp M, et al. The gut microbiome as novel cardio-metabolic target: the time has come! Eur Heart J 2014;35(14):883-7.
8. Brown JM, Hazen SL. Meta-organismal nutrient metabolism as a basis of cardiovascular disease. Curr Opin Lipidol 2014; 25(1):48-53.
9. Backhead F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA 2004;101(44):15718-23.
10. Velagapudi VR, Hezaveh R, Reigstad CS, et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010;51(5):1101-12.
11. Delzenne NM, Cani PD. Gut microbiota and the pathogenesis of insulin resistance. Curr Diab Rep 2011;11(3):154-9.
12. Aron-Wisnewsky J, Gaborit B, Dutour A, et al. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013;19(4):338-48.
13. Griffin JL, Scott J, Nicholson JK. The influence of pharmacogenetics on fatty liver disease in the Wistar and Kyoto rats: A combined transcriptomic and metabolomic study. J Proteome Res 2007;6(1):54-61.
14. Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013;499(7456):97-101.
15. Sjögren K, Engdahl C, Henning P, et al. The gut microbiota regulates bone mass in mice. J Bone Miner Res. 2012;27(6):1357-67.
16. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012;126(9):1110-20.
17. Tremaroli V, Bachhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489 (7415):242-9.
18. Lozupone CA, Stombaugh JI, Gordon JI et al. Diversity, Stability and resilience of the human gut microbiota. Nature 2012; 489 (7415): 220-30
19. Tilg H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J Clin Gastroecterol 2010; 44 (Suppl. 1): 16-8.
20. Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human microbiota. Science 2013; 341(6141): 1237439.
21. Ding T, Schloss PD. Dynamics and associations of microbial community types across the human body. Nature 2014;509(7500):357-60.
22. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. MetaHIT Consortium. Nature 2010;464(7285):59-65.
23. Kostyukevich OI. Influence of intestinal microflora on human health. From Pathogenesis to modern methods of correction of dysbiosis. Rossiyskiy meditsinskiy zhurnal 2011; 5: 304-8. In Russian (Костюкевич О.И. Влияние кишечной микрофлоры на здоровье человека. От патогенеза к современным методам коррекции дисбиоза. Российский медицинский журнал 2011; 5:304-8).
24. Kushnir IE. Intestinal microbiota and human health. Modern approaches to intestinal dysbiosis correction. Zdorov'e Ukrainy 2015; 1: 41-3. In Russian (Кушнир И.Э. Микробиота кишечника и здоровье человека. Современные подходы к коррекции дисбиоза кишечника. Здоровье Украины 2015;1:41-3).
25. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 2014;124(10):4204-11.
26. Micha R, Wallace SR, Mozaffarian D. Red and processed meat consumption and risk of incident coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis. Circulation 2010; 121(21):2271-83.
27. Wang Z, Klipfell E, Bennett BJ et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472: 57-63.
28. Bennett BJ, De Aguiar Vallim TQ, Wang Z et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metabolism 2013; 17(1):49-60.
29. Tang WH, Wang Z, Levison BS et al. Intestinal Microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013; 368:1575-84.
30. Prospective Studies collaboration, Lewington S, Whitlock G, et al. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829-39.
31. Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite, trimethylamine-N-oxide, in parents with heart failure: refining the gut hypothesis. О Am Coll Cardiol 2013; 64(18):1908-14.
32. Bell JD, Lee JA, Lee HA et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. Biochim Biophys Acta 1991; 1096(2):101-7.
33. Rhee EP, Clish CB, Ghorbani A, et al. A combines epidemiologic and metabolomics approach improves CKD prediction. О Am Soc Nephrol 2013;24(8):1330-38.
34. Gao X, Liu X, Xu J, et al. Dietary trimethylamine-N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng 2014:118(4):476-81.
35. Ierardi E, Sorrentino C, Principi M, et al. Intestinal microbial metabolism of phosphatidylchline: a novel insight in the cardiovascular risk scenario. Hepatobiliary Surg Nutr 2015;4(4):289-92.
36. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013;19(5):576-85.
37. Wang D, Xia M, Yan X, et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ Res 2012; 111(8):967-81.
38. Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis 2011;34(1):3-15.
39. Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006;103(33):12511-6.
40. Bain MA, Faull R, Milne RW, et al. Oral L-carnitine: metabolite formation and hemodialysis. Curr Drug Metab 2006;7(7):811-6.
41. Marcovina SM, Sirtori C, Peracino A, et al. Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Transl Res 2013;161(2):73-84.
42. Pan A, Sun Q, Bernstein AM, et al. Red meat consumption and mortality: results from 2 prospective cohort studies. Arch Intern Med 2012; 172(7):555-63.
43. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505(7484):559-63.
44. Lekawanvijit S, Kumfu S, Wang BH, et al. The uremic toxin absorbent AST-120 abogates cardiorenal injury following myocardial infarction. PLoS One 2013;8(12):e83687.
45. Ito S, Higuchi Y, Yagi Y, et al. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease. J Leukoc Biol 2013;93(6):837-45.
46. Backhed F, Manchester JK, Semenkovich CF, et al. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 2007; 104(3):979-84.
47. Тurnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006;444:1027-31.
48. Gregory JC, Buffa JA, Org E, et al. Transmission of Atherosclerosis Susceptibility with Gut Microbial Transplantation. J Biol Chem 2015;290(9):5647-60.
49. Serino M, Blasco-Baque V, Nicolas S, et al. Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep 2014; 16(11):540.
50. Messenger J, Clark S, Massick S, et al. A review of trimethylaminuria: (fish odor syndrome). О Clin Aesthet Dermatol 2013;6(11):45-8.
51. Hartiala J, Bennett BJ, Tang WH, et al. Comparative genome-wide association studies in mice and humans for trimethylamine-N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol 2014;34(6):1307-13.